



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Moore et al.

Group No.: 1645

Application Serial No.: 09/975,253

Examiner: Unassigned

Filed: October 12, 2001

Attorney Docket No.: PF196P1

For: Methods and Compositions for Treating
and Preventing Infection Using Human Interferon
Regulatory Factor 3

RESPONSE TO REQUEST UNDER 42 U.S.C. 2182

ATTN: LICENSING AND REVIEW SECTION
Commissioner For Patents
Washington, D.C. 20231

RECEIVED

APR 15 2002

Sir:

TECH CENTER 1600/2900

TECH CENTER 1600/2900

MAR 26 2002

RECEIVED

The Licensing and Review section has issued an informal request, mailed February 4, 2002, for a statement regarding the relationship of the instant invention to the performance of any work under any contract or other arrangement with the Department of Energy (DOE). Although Applicants believe that this request has been issued in error, submitted herewith are declarations under 42 U.S.C. 2182, signed by Paul A. Moore and Paula Pitha-Rowe, inventors of the instant application, setting forth (i) the circumstances under which the invention was made and conceived; and (ii) that the invention was not made or conceived in connection with any contract or arrangement with, or for the benefit of, the United States Atomic Energy Commission or its successors: Energy Research and Development Administration or the Department of Energy.

No fee is believed due in connection with this submission. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 08-3425.

Respectfully submitted,

Dated: March 21, 2002

Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
301-610-5772 (telephone)

MMW/JS